Merck KGaA (MKGAF) Q2 2025 Earnings Call Transcript

Merck KGaA reported Q2 2025 organic sales growth of 2% and organic EBITDA pre growth of 5%, driven by robust performance in Healthcare and Life Science, which each grew 4% organically, notably from Mavenclad and Process Solutions' 11% organic sales increase and strong order intake. Conversely, Electronics' organic sales declined 6% due to significant DS&S project delays, with its EBITDA pre heavily impacted by non-recurring items and FX headwinds. Despite these challenges, Merck maintained its full-year absolute EBITDA pre guidance midpoint and raised its organic EBITDA pre growth outlook to 4-8%, while narrowing group organic sales growth to 2-5% and adjusting reported figures for increased currency headwinds and portfolio shifts from the SpringWorks acquisition and Surface Solutions divestiture.

Analysis

Merck KGaA demonstrated resilient underlying performance in Q2 2025, delivering 2% group organic sales growth and a more pronounced 5% organic EBITDA pre growth, signaling effective cost management despite significant currency headwinds that reduced reported sales by 4.2%. The results revealed a clear divergence between business sectors. Both Life Science and Healthcare were primary growth engines, each expanding 4% organically. The Life Science division's performance was highlighted by an 11% organic sales surge in Process Solutions, supported by a book-to-bill ratio comfortably above 1, indicating customer destocking is complete and order momentum is strong. Healthcare's growth was driven by a 20.7% increase in Mavenclad sales and solid performance from its CM&E portfolio. Conversely, the Electronics segment acted as a significant drag, with sales declining 6% organically due to a more than 30% drop in the DS&S business from customer project delays now extending beyond 2025. The Electronics EBITDA pre was further impacted by two non-recurring items, which accounted for a 7 percentage point drag on the segment's margin. In light of these dynamics, management has updated its full-year guidance, narrowing organic sales growth to a +2% to +5% range while raising its organic EBITDA pre growth forecast to +4% to +8%, reflecting confidence in profitability despite downgrading the outlook for the Electronics division.

Key Decisions for Investors

• Investors should focus on the upgraded organic EBITDA pre guidance of +4% to +8%, which signals strong underlying profitability and cost control that is offsetting significant FX headwinds and portfolio dilution.
• The robust performance in Life Science, particularly the 11% growth and strong book-to-bill ratio in Process Solutions, should be viewed as a key positive indicator of demand recovery and a primary driver for achieving full-year targets.
• The severe weakness in the Electronics division, where sales guidance was cut to a range of -5% to -1% due to extended project delays in DS&S, represents the most significant risk and warrants close monitoring for any signs of market stabilization.
• The recent portfolio moves, including the SpringWorks acquisition and Surface Solutions divestiture, increase exposure to high-growth pharma assets; tracking the sales ramp-up of Ogsiveo and Gomekli is critical for assessing the long-term value of this strategic shift.